Subcutaneous heparin (Calciparine) at subanticoagulant doses did not improve early renal allograft function in a randomized trial. This treatment also increased the risk of hemorrhagic complications compared to placebo.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: